Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

1,620 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Federal Court Dismisses Apotex's Application For Judicial Review Regarding Apo-Progesterone ANDS

    That the U.S. Food and Drug Administration had previously approved a different drug product with higher levels of SLS did not render the decision unreasonable.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Rose Carter On Patient Safety In Current Medical Research And Opinion

    Rose Carter co-authored the article "Tool to assess causality of direct and indirect adverse events associated with therapeutic interventions" in Current Medical Research and Opinion.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Bennett Jones LLP
Bennett Jones LLP
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2022

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2022.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2023

    On April 1, 2023, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,952 to $10,152 in accordance with subsection 9(1)...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2024

    On April 1, 2024, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $10,152 to $10,356 in accordance with subsection 9(1) of the Certificate...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificates Of Supplementary Protection Filing Fee Increase Effective April 1, 2020

    On April 1, 2020, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,376 to $9,564 in accordance with subsection 9(1) of the...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificates Of Supplementary Protection Filing Fee Increase Effective April 1, 2021

    On April 1, 2021, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,564 to $9,756 in accordance with subsection 9(1) of the Certificate of Supplementary...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Video

    Generic Damages In Life Sciences Patent Litigation: Strategic Considerations (Video Content)

    A discussion on the strategic considerations relating to generic damages in life sciences patent litigation.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Gowling WLG
    Gowling WLG
  • Article

    Intellectual Property Weekly Abstracts Bulletin - Week Of January 16, 2012

    A revised NPDUIS Analytical Study Wholesale Up-charge Policies of Canada’s Public Drug Plans has been published on the Patented Medicine Prices Review Board website.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Borden Ladner Gervais LLP
    Borden Ladner Gervais LLP
  • Article

    PMPRB Issues A Notice Of Hearing For Allegations Of Excessive Pricing Of PROCYSBI

    The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling ...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    PMPRB Posts Submissions From Guidelines Consultation; Federal Court Challenge Of Amended Regulations Rescheduled

    As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    PMPRB Releases CompassRx Report For 2019/2020

    The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    CIPO Expected To Resume Patent Granting On August 20

    As we previously reported, the Canadian Intellectual Property Office (CIPO) has not issued patents since July 2, 2024. According to CIPO's updated roadmap, patent granting should resume on August 20, 2024.
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Court Permits Amendment Of Patent Record To Remove Inventors And Co-owner

    In H. Lundbeck v Canada (Commissioner of Patents), 2021 FC 1394, the Court granted an application to amend a patent record to remove inventors and a co-owner.
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Views From The Market Podcast: Episode 53 - Life Sciences And Healthcare: Making M&A Work In A Highly Regulated Environment

    Mario's guest for this podcast is Sara Zborovski, a partner at Stikeman Elliott and leader of the firm's life sciences and healthcare regulatory practice.
    CanadaCorporate/Commercial Law
    Stikeman Elliott LLP
    Stikeman Elliott LLP
  • Article

    Supreme Court Of Canada Dismisses Apotex's Application For Leave To Appeal Double-Patenting Decision

    On April 28, 2017, the Supreme Court of Canada dismissed Apotex's application for leave to appeal a decision of the Federal Court of Appeal
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    2021 PMPRB Annual Report

    On November 21, 2022, the Minister of Health tabled the 2021 Annual Report of the Patented Medicine Prices Review Board.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Bill C-30 Receives Royal Assent

    As previously reported here, Bill C-30 was passed by the Senate on May 11, 2017. Bill C-30 is the bill that will implement the Canada-European Union Comprehensive Economic and Trade Agreement (CETA).
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Health Canada Launches E-Learning Tool For Understanding Premarket Regulatory Requirements For Medical Devices

    On March 19, 2019, Health Canada published a Notice, announcing the launch of its e-Learning tool: Understanding How Medical Devices are Regulated in Canada – Premarket Regulation.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Quebec Initiating A Shift To Use Of Biosimilar Drugs

    As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Showing 1–20 of 1620 results

    Next
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics